209 related articles for article (PubMed ID: 30687320)
1. Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice.
Perez-Chacon G; Adrados M; Vallejo-Cremades MT; Lefebvre S; Reed JC; Zapata JM
Front Immunol; 2018; 9():3114. PubMed ID: 30687320
[TBL] [Abstract][Full Text] [Related]
2. The
Perez-Chacon G; Zapata JM
Front Immunol; 2021; 12():627602. PubMed ID: 33912159
[TBL] [Abstract][Full Text] [Related]
3. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice.
Zapata JM; Krajewska M; Morse HC; Choi Y; Reed JC
Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16600-5. PubMed ID: 15545599
[TBL] [Abstract][Full Text] [Related]
4. Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer.
Zapata JM; Llobet D; Krajewska M; Lefebvre S; Kress CL; Reed JC
Blood; 2009 May; 113(19):4595-603. PubMed ID: 19074733
[TBL] [Abstract][Full Text] [Related]
5. BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma.
Burkhard R; Bhagat G; Cogliatti SB; Rossi D; Gaidano G; Pasqualucci L; Novak U
Hematol Oncol; 2015 Mar; 33(1):23-30. PubMed ID: 24496723
[TBL] [Abstract][Full Text] [Related]
6. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.
Edwards SK; Moore CR; Liu Y; Grewal S; Covey LR; Xie P
BMC Cancer; 2013 Oct; 13():481. PubMed ID: 24131623
[TBL] [Abstract][Full Text] [Related]
7. Genetic inactivation of TRAF3 in canine and human B-cell lymphoma.
Bushell KR; Kim Y; Chan FC; Ben-Neriah S; Jenks A; Alcaide M; Fornika D; Grande BM; Arthur S; Gascoyne RD; Steidl C; Morin RD
Blood; 2015 Feb; 125(6):999-1005. PubMed ID: 25468570
[TBL] [Abstract][Full Text] [Related]
8. TRAF2/3 deficient B cells resist DNA damage-induced apoptosis via NF-κB2/XIAP/cIAP2 axis and IAP antagonist sensitizes mutant lymphomas to chemotherapeutic drugs.
Vashisht M; Ge H; John J; McKelvey HA; Chen J; Chen Z; Wang JH
Cell Death Dis; 2023 Sep; 14(9):599. PubMed ID: 37679334
[TBL] [Abstract][Full Text] [Related]
9. TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.
Whillock AL; Ybarra TK; Bishop GA
J Biol Chem; 2021; 296():100465. PubMed ID: 33639170
[TBL] [Abstract][Full Text] [Related]
10. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia.
Egle A; Harris AW; Bath ML; O'Reilly L; Cory S
Blood; 2004 Mar; 103(6):2276-83. PubMed ID: 14630790
[TBL] [Abstract][Full Text] [Related]
11. TRAF3 Acts as a Checkpoint of B Cell Receptor Signaling to Control Antibody Class Switch Recombination and Anergy.
Chen Z; Krinsky A; Woolaver RA; Wang X; Chen SMY; Popolizio V; Xie P; Wang JH
J Immunol; 2020 Aug; 205(3):830-841. PubMed ID: 32591397
[TBL] [Abstract][Full Text] [Related]
12. Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice.
Lalani AI; Moore CR; Luo C; Kreider BZ; Liu Y; Morse HC; Xie P
J Immunol; 2015 Jan; 194(1):334-48. PubMed ID: 25422508
[TBL] [Abstract][Full Text] [Related]
13. Rearrangement of the 5' cluster region of the BCL2 gene in lymphoid neoplasm: a summary of nine cases.
Yabumoto K; Akasaka T; Muramatsu M; Kadowaki N; Hayashi T; Ohno H; Fukuhara S; Okuma M
Leukemia; 1996 Jun; 10(6):970-7. PubMed ID: 8667654
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs.
Xie P; Stunz LL; Larison KD; Yang B; Bishop GA
Immunity; 2007 Aug; 27(2):253-67. PubMed ID: 17723217
[TBL] [Abstract][Full Text] [Related]
15. Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions.
Yi Z; Lin WW; Stunz LL; Bishop GA
Cytokine Growth Factor Rev; 2014 Apr; 25(2):147-56. PubMed ID: 24433987
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
17. Novel murine B-cell lymphoma/leukemia model to study BCL2-driven oncogenesis.
Meijerink JP; Van Lieshout EM; Beverloo HB; Van Drunen E; Mensink EJ; Macville M; Pieters R
Int J Cancer; 2005 May; 114(6):917-25. PubMed ID: 15645425
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.
Nakagawa M; Tsuzuki S; Honma K; Taguchi O; Seto M
Haematologica; 2011 Sep; 96(9):1318-26. PubMed ID: 21606168
[TBL] [Abstract][Full Text] [Related]
19. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
20. Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW.
Adams CM; Mitra R; Gong JZ; Eischen CM
Clin Cancer Res; 2017 Nov; 23(22):7119-7129. PubMed ID: 28855351
[No Abstract] [Full Text] [Related]
[Next] [New Search]
